With effect from January 1, 2012, Artimplant will take over responsibility for sales of Artelon® CMC Spacer, previously handled by the licensee SBi. This is an integral part of Artimplant's focus on reinforcing its presence on the very important US market.
Since December 2011, Artimplant has had a stronger sales
organization in place in the USA, which it is felt will
contribute positively to the company's presence and
sales volumes. By assuming responsibility for sales of
Artelon® CMC Spacer and other products for restoring joint
surfaces, Artimplant will have a more complete product
offering on the US market. Artelon® CMC Spacer is
considered to have major market potential, which Artimplant
is in a better position to develop by assuming direct
control of sales.
The former licensee, SBI, will cease sales of Artimplant
products for restoring joint surfaces in conjunction with
Artimplant taking back the sales rights for these
products.
Västra Frölunda, January 3, 2012
Kjell Thörnbring
For further information, please contact:
Kjell Thörnbring, CEO
E-mail: kjell.thornbring@artimplant.com
Telephone: +46 703 11 90 25
Further information at www.artimplant.com where one also
can subscribe to future press releases;
www.artimplant.com/investors-media/subscribe-to-press-releases.html
 (http://www.artimplant.com/investors-media/subscribe-to-press-releases.html)Artimplant
Artimplant is a biomaterials company focused on solutions
to problems in orthopedic and oral surgery. We restore
health through the development, production and marketing of
degradable implants that regenerate body functions and
improve quality of life. Our products, made from Artelon®,
meet unmet clinical needs and are marketed in a growing
number of therapy areas. Artimplant produces implants for
treatment of osteoarthritis in hands and feet, for shoulder
and other soft tissue injuries as well as oral
applications.
Artimplant is a public company listed on the OMX Nordic
Exchange Stockholm in the Small Cap segment and in the
healthcare sector.
Forward-looking statements
This press release contains forward-looking statements as
defined in the U.S. Private Securities Litigation Reform
Act of 1995. Readers are cautioned not to place undue
reliance on these forward-looking statements. Actual
results may differ materially from those indicated by these
forward-looking statements as a result of risks and
uncertainties impacting the Company's business
including increased competition; the ability of the Company
to expand its operations and to attract and retain
qualified professionals; technological obsolescence;
general economic conditions; and other risks detailed from
time to time in the Company's filings.
This is information which Artimplant shall make public
pursuant to the Swedish Financial Instruments Act and the
Swedish Securities Exchange and Clearing Operations Act
and/or stock market agreements. Information was made
available for publication on January 3, 2012 at 11:00 AM
(Swedish time).
The following files are available for download:
distribué par | Ce noodl a été diffusé par Artimplant AB et initialement mise en ligne sur le site http://www.artimplant.se. La version originale est disponible ici. Ce noodl a été distribué par noodls dans son format d'origine et sans modification sur 2012-01-03 11:13:10 AM et restera accessible depuis ce lien permanent. Cette annonce est protégée par les règles du droit d'auteur et toute autre loi applicable, et son propriétaire est seul responsable de sa véracité et de son originalité. |